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Abstract
Background: On dialysis, survival among patients with diabetes mellitus is inferior to survival of non-diabetic
patients. We hypothesized that patients with diabetes as primary renal disease have worse survival compared to
patients with diabetes as a co-morbid condition and aimed to compare all-cause mortality between these patient
groups.
Methods: Data were collected from the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD), a
multicenter, prospective cohort study in which new patients with end stage renal disease (ESRD) were monitored
until transplantation or death. Patients with diabetes as primary cause of ESRD were compared with patients with
diabetes as co-morbid condition and both of these patient groups were compared to patients without diabetes.
Analysis was performed using Kaplan-Meier and Cox regression.
Results: Fifteen % of the patients had diabetic nephropathy as primary renal disease (N = 281); 6% had diabetes as
co-morbid condition (N = 107) and 79% had no diabetes (N = 1465). During follow-up 42% of patients (N = 787)
died. Compared to non-diabetic patients, mortality risk was increased for both patients with diabetes as primary
renal disease HR: 1.9 (95% CI 1.6, 2.3) and for patients with diabetes as co-morbid condition HR: 1.7 (95% CI 1.3,
2.2). Mortality was not significantly higher in patients with diabetes as primary renal disease compared to patients
with diabetes as co-morbid condition (HR 1.06; 95% CI 0.79, 1.43).
Conclusions: This study in patients with ESRD showed no survival difference between patients with diabetes as
primary renal disease and patients with diabetes as a co-morbid condition. Both conditions were associated with
increased mortality risk compared to non-diabetic patients.
Background
Diabetes mellitus is a major contributor to the develop-
ment of renal failure [1-3]. The proportion of patients
with diabetes mellitus that progresses to End Stage Renal
Disease (ESRD) is increasing. The increased prevalence of
diabetes mellitus is estimated to account for 28% of the
increased incidence of renal replacement therapy (RRT) in
general [4,5]. A marked difference exists in incidence of
patients with ESRD due to diabetic nephropathy between
Europe and the United States. The percentage of patients
entering RRT because of diabetic nephropathy is 10-15%
[5] in Europe compared to 45% in the United States [6].
Survival of diabetic patients and non- diabetic patients
with ESRD has improved in the past 10 years [5,7,8].
However, survival among diabetic dialysis patients
remains inferior to that of non- diabetic patients [2,9].
Patients with diabetic nephropathy have the largest num-
ber of co-morbid conditions within the ESRD population
[4]. These conditions are mainly vascular in nature
[9-11]. One can hypothesize that in patients with diabetic
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but also involves other organs resulting in retinopathy,
neuropathy and cardiovascular complications. In con-
trast, patients on dialysis with diabetes as a co-morbid
condition may have less pronounced organ damage.
Therefore, survival in patients on dialysis with diabetes as
co-morbid condition may be better compared to patients
with ESRD due to diabetic nephropathy. However, at pre-
sent this is unknown.
The aim of our present study was therefore to compare
survival of dialysis patients with diabetes mellitus as pri-
mary cause of the renal failure with dialysis patients with
diabetes mellitus as co-morbid condition. Mortality rates
in these two groups were compared to mortality rates in
dialysis patients without diabetes mellitus. Because of the
high incidence of cardiovascular morbidity and mortality
in the dialysis population, especially in patients with dia-
betes, cardiovascular mortality was compared between the
three groups. In addition, we performed a stratified analy-
sis according to treatment modality.
Methods
Patient selection
Patients who were ≥ 18 years and who began chronic dia-
lysis as the initial renal replacement therapy were eligible
for this study. Three months after the start of dialysis was
considered as the baseline of present analyses. Informed
consent was obtained before inclusion. This study was
approved by the Medical Ethics Committees of all partici-
pating centres.
Design
The Netherlands Cooperative Study on the Adequacy of
Dialysis (NECOSAD) is a multicenter, prospective cohort
study in 38 dialysis centres throughout the Netherlands.
New patients with ESRD were included at the time of
initiation of dialysis treatment, from January 1, 1997 and
were monitored at 3, 6 and thereafter at 6 month intervals
until renal transplantation, death or January 1, 2007. Data
on demographic characteristics, co-morbidities and pri-
mary kidney disease were collected at the time of entry
into the study. Dialysis characteristics were collected 3
m o n t h sa f t e rt h es t a r to fR R Ta n da t6m o n t hi n t e r v a l s
thereafter. At the 3 month visit (baseline) patients were
classified according to the treatment modality, i.e. perito-
neal dialysis (PD) or hemodialysis (HD). The type and
cause of renal disease and causes of death were defined
according to the criteria of the European Renal Associa-
tion- Dialysis and Transplantation Association [12].
Diabetes mellitus
For the present analysis patients were categorized as fol-
lows: 1. patients with diabetic nephropathy as the pri-
mary cause of ESRD (diabetes glomerulosclerosis or
diabetic nephropathy, type 1 and type 2) [10] and 2.
patients with diabetes mellitus as a co-morbid condition,
but without diabetic nephropathy as a primary cause of
ESRD, and 3. patients with ESRD without diabetes
mellitus.
Study endpoints
The primary endpoint of the present analysis was all
cause mortality. Cardiovascular mortality rates were cal-
culated. Cardiovascular mortality was defined as death
attributed to myocardial ischemia and infarction, heart
failure, cardiac arrest, and cause of death uncertain/not
determined [13]. Cause of death uncertain/not deter-
mined was considered as cardiovascular death because
most of these patients died of a sudden death syndrome
and this syndrome had a cardiovascular origin.
Statistical analysis
Mortality was calculated as incidence rate and expressed
as number of deaths/1000 person years. Time to event
analysis was performed using Kaplan Meier analysis and
the Cox proportional hazard’sm o d e l .H a z a r dr a t i o s( H R )
were calculated for comparison of all-cause and cardio-
vascular mortality in the 3 groups. All registered deaths
during the follow up period were allocated to treatment
modality at the 3 month visit, ignoring modality switches
(intention to treat analysis). The multivariate Cox pro-
portional hazards model was extended with adjustments
for the possible confounding effects of age and gender.
Other clinical characteristics at baseline (such as hyper-
tension, cardiovascular disease) were considered to be
potential consequences of diabetes, and thus not used as
confounders in multivariate analyses [14]. In an addi-
tional analysis the effects of treatment modality (perito-
neal dialysis versus hemodialysis) on mortality were
studied. All analyses were performed with SPSS statistical
software, version 14.0.
Results
Patient characteristics
Between January 1997 and January 2007, 1853 patients
who survived the first 3 months of dialysis were included.
Fifteen percent of patients had diabetes mellitus as pri-
mary renal disease, 6% of patients had diabetes as a co-
morbid condition whereas the majority of the cohort
(79%) had a renal disease without diabetes (Table 1).
Patients with diabetes as co-morbid condition were older
at baseline (median age 69, range 28-86 y) compared
to patients with diabetes as primary renal disease (63, 28-
84 y) and patients without diabetes (62, 18-92 y). Retino-
pathy for which laser coagulation therapy was performed
was more frequent in patients with diabetes as primary
renal disease compared to patients with diabetes as a co-
morbid condition (62% versus 11%). During follow-up
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Page 2 of 733% of the patients without diabetes received a renal
transplant compared to 17% of the patients with diabetes
as primary renal disease and 8% of the patients with dia-
betes as a co-morbid condition.
Mortality
During follow up, 787 patients (42%) of the total group
died. The overall mortality rates and cardiovascular mor-
tality rates for each patient group are shown in table 2.
Mortality was higher in patients with diabetes as primary
renal disease (HR 1.9; 95% CI 1.6, 2.2) and in those with
diabetes as a co-morbid condition (2.1, 95% CI 1.6, 2.7)
compared to patients without diabetes (Figure 1). After
adjustment for age and gender, the HR for patients with
diabetes as primary renal disease was 1.9 (95% CI 1.6,
2.3) and 1.7 (95% CI 1.3, 2.2) for patients with diabetes as
a co-morbid condition, as compared to non-diabetic
patients. Further adjustment for smoking, blood pressure,
body mass index, serum albumin, myocardial infarction
or stroke, the HR for patients with diabetes as primary
renal disease was 1.8 (95% CI 1.3, 2.4) and 1.8 (95% CI
1.5, 2.3) for patients with diabetes as a co-morbid condi-
tion, as compared to non-diabetic patients. Also mortal-
ity in patients with diabetes as primary renal disease was
not clearly higher compared to patients with diabetes as
co-morbid condition (HR 1.06; 95% CI 0.79, 1.43).
Table 1 Baseline characteristics at 3 months after the start of dialysis
Diabetes as
primary renal
disease
N = 281
Diabetes as
co-morbid
condition
N = 107
Without
diabetes
N = 1465
P value*
Age (median yr) 63 (28-84) 69 (28-86) 62 (18-92) 0.00
Male gender (%) 54 58 64 0.01
Primary renal disease (%)
Diabetes Mellitus 100 0 0
Glomerulonephritis 0 22 24
Renal Vascular disease 0 22 19
All other 0 56 58
Modality of dialysis (%)
HD 64 75 62 0.03
Comorbidity (%)
Myocardial infarction 14 30 11 0.00
Cerebrovascular disease 15 9 7 0.00
Peripheral vascular disease 23 26 12 0.00
Retinopathy
(lasercoagulation) (%)
62 11 0
Medication: (%)
antihypertensive agents 89 79 82 0.01
ACEi, ARBs 36 28 21 0.36
Use of insulin s.c.(%) 75 36 0
Blood pressure (mean, mm Hg)
Systolic 154 (90-260) 151 (100-210) 148 (90-234) 0.00
Diastolic 79 (44-120) 80 (54-115) 84 (44-145) 0.00
Smoking (%) 14 23 24 0.01
Body Mass Index (kg/m2) 27 (16-44) 26 (16-45) 25 (15-56) 0.00
Haemoglobin (g/dl) 11 (6-16) 11 (6-14) 11 (6-23) 0.11
Albumin (mmol/l) 34 (14-47) 35 (13-46) 36 (14-67) 0.02
Residual GFR (ml/min) 6 6 5 0.06
*p-value: for continuous variables we used Anova analysis and for binary analysis we used Chi-Square analysis.
Table 2 Effect of treatment modality on survival; overall
mortality and cardiovascular mortality rate on six patient
groups
Patient group Overall mortality rate
(Number/
1000 person years)
Cardiovascular mortality rate
(Number/
1000 person years)
No DM 140 41
DM PRD 242 93
DM co-M 288 69
No DM denotes patients without diabetes mellitus
DM PRD denotes patients with diabetes as primary renal disease
DM co-M denotes patients with diabetes as a co-morbid condition
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Thirty-seven percent of patients started on PD (N =
684). Five hundred and fifty five patients had no dia-
betes, 102 patients had diabetes as primary renal disease
and 27 patients had diabetes as a co-morbid condition.
After 3 months a few patients switched to hemodialysis;
15 patients without diabetes, 3 patients with diabetes as
primary renal disease and none of the patients with dia-
betes as a co-morbid condition. The highest mortality
r a t ew a so b s e r v e di np a t i e n t sw i t hd i a b e t e sa sp r i m a r y
renal disease on PD (Figure 2). Following adjustment for
age and gender the HR for PD patients with diabetes
mellitus as primary renal disease was 2.7 (95% CI 2.0,
3.7) and 1.2 (95% CI 0.7, 2.1) for PD patients with dia-
betes as a co-morbid condition compared to the refer-
ence group of PD patients without diabetes (Table 3).
Sixty-three percent (N = 1169) of patients started on HD.
Nine hundred and ten patients had no diabetes, 179
patients had diabetes as primary renal disease and 80
patients had diabetes as a co-morbid condition. After 3
months a few patients switched to peritoneal dialysis; 39
patients without diabetes, 3 patients with diabetes as
primary renal disease and 5 patients with diabetes as a co-
morbid condition. HD patients with diabetes as a co-
morbid condition had the highest mortality rates (Figure 2).
Adjusted for age and gender the HR for HD patients with
diabetes as primary renal disease was 1.8 (95% CI 1.4, 2.3)
and 2.0 (95% CI 1.4, 2.8) for HD patients with diabetes as a
co-morbid condition compared to the reference group
(Table 3). Further adjustment for smoking, blood pressure,
body mass index, serum albumin, myocardial infarction or
stroke did not materially influence the study results in HD
and PD patients. After these adjustments the HR in PD
patients with diabetes as primary renal disease was 2.9 (95%
CI 2.1, 4.0) and 1.2 (95% CI 0.7, 2.3) for PD patients with
diabetes as a co-morbid condition compared to the refer-
ence group. The HR in HD patients with diabetes as pri-
mary renal disease was 1.7 (95% CI 1.3, 2.3) and 1.9 (95%
CI 1.3, 2.7) for HD patients with diabetes as a co-morbid
condition compared to the reference group.
Discussion
In this cohort study we compared survival in patients with
ESRD caused by diabetic nephropathy to patients with dia-
betes as a co-morbid condition and patients without dia-
betes. Survival in dialysis patients with diabetes was not
different between patients with diabetes as primary renal
disease and to patients with diabetes as a co-morbid condi-
tion. On HD the mortality risk in patients with diabetes as
primary renal disease or diabetes as co-morbid condition
Number of patients 
at risk (n) 
0  2  4  6  8 
No DM  1465  792  371  114  30 
DM as 
PRD  281  144  42  12  3 
DM as  
co-morb  107  44  18  5  0 
Figure 1 Kaplan Meier; Survival of patients with diabetes as primary renal disease (DM PRD) compared to patients with diabetes as a
co-morbid condition and patients without diabetes mellitus.
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without diabetes. Furthermore the mortality risk in PD
patients with diabetes as primary renal disease was
increased compared to patients without diabetes, whereas
this was not the case in PD patients with diabetes as a co-
morbid condition.
T oo u rk n o w l e d g e ,t h i si st h ef i r s ts t u d yt h a ti n v e s t i -
gated mortality in ESRD separately for patients with dia-
betes as a co-morbid condition and a non-diabetic
primary diagnosis of renal disease of different cause. A
previous study with a limited number of patients, showed
that diabetic patients with a primary diagnosis of adult
polycystic kidney disease exhibit a similar survival com-
pared to patients with a primary diagnosis of diabetic
nephropathy [15]. Villar et al showed that patients with
diabetic nephropathy had a significant worse outcome
compared to patients with glomerular nephropathy with
a HR of 1.2 [8]. Other studies compared dialysis patients
with diabetic nephropathy as primary renal disease to
dialysis patients without diabetic nephropathy and
showed impaired survival for patients with diabetic
nephropathy [6,16]. Present study adds that survival in
dialysis patients was not different between patients with
diabetes as primary renal disease and patients with dia-
betes as a co-morbid condition. These results provide
important clinical information: diabetes mellitus has a
very strong impact on survival even if it is not the pri-
mary cause of ESRD.
However, this finding was in contrast with our expecta-
tion since we presumed a betterp r o g n o s i sf o rp a t i e n t s
with diabetes as a co-morbid condition compared to
patients with diabetes as primary renal disease for the
reason that in patients with diabetes as co-morbid condi-
tion organ damage due to diabetes mellitus might be less
pronounced. In accordance with this notion, at baseline
patients with diabetes as a co-morbid condition showed
less retinopathy compared to patients with diabetes as a
primary renal disease. However the prevalence of myo-
cardial infarction was higher in patients with diabetes as
Number of 
patients at risk 
 
0  2  4  6  8 
No DM  910  489  227  72  24 
DM as 
PRD  179  91  29  9  2 
DM as 
comorb  80  28  11  2  0 
Number of 
patients at risk 
 
0  2  4  6  8 
No DM  555  303  144  42  6 
DM as 
PRD  102  51  13  3  1 
DM as 
comorb  27  16  7  2  0 
Figure 2 Kaplan Meier; Survival of patients with diabetes as primary renal disease (DM PRD) versus patients with diabetes as a co-
morbid condition and patients without diabetes mellitus in patients on hemodialysis (A) and peritoneal dialysis (B).
Table 3 Effect of treatment modality on survival; a cox
model on six patient groups
Patient group Hazard Ratio
adjusted
95% Confidence
interval
Peritoneal dialysis
No DM 1.0 2.0, 3.7
DM PRD 2.7 0.7, 2.1
DM co-M 1.2
Hemodialysis
No DM 1.1 0.9, 1.3
DM PRD 1.8 1.4, 2.3
DM co-M 2.0 1.4, 2.8
Data were adjusted for age and gender
No DM denotes patients without diabetes mellitus
DM PRD denotes patients with diabetes as primary renal disease
DM co-M denotes patients with diabetes as a co-morbid condition
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different age distribution. A possible explanation for the
poor outcome in patients with diabetes as a co-morbid
condition could be the additional risk of diabetes in
ESRD patients who were already cardiovascular compro-
mised due to their non-diabetic renal disease. Patients
with ESRD without diabetes have a high risk of cardio-
vascular morbidity and mortality [17], just like patients
with diabetes mellitus [10,11].
We observed a difference in survival related to treatment
modality of ESRD. The mortality risk in PD patients for
diabetes as primary renal disease was increased compared
to patients without diabetes, whereas this was not the case
in PD patients with diabetes as co-morbid condition. The
fact that we could not found a difference in PD patients
with diabetes as a co-morbid condition could be due to
limited power. In PD, dialysis fluids consist of high glucose
solutions. These fluids also contained high concentration
of glucose degradation products. The peritoneal absorp-
tion of glucose degradation products might enhance for-
mation of Advanced Glycosylation End products (AGEs);
a non enzymatic reaction of reducing sugars with proteins
[18,19]. Accumulation of AGEs is different in PD patients
compared to HD patients. A study, determining the influ-
ence of dialysis modality on plasma and tissue concentra-
tions of a specific AGE pentosidine, showed that plasma
pentosidine levels were significantly lower in PD patients
compared with HD patients. In contrast, peritoneal con-
centrations of pentosidine were significantly higher in
patients on PD compared to patients on HD [20]. AGEs
may play a role in the pathogenesis of diabetic nephropa-
thy [21]. Therefore accumulation of AGEs might be differ-
ent in patients with diabetes as primary renal disease as
o p p o s e dt op a t i e n t sw i t hd i a b e t e sa sac o - m o r b i dc o n d i -
tion. It might be useful to measure serum and peritoneal
levels of circulating AGEs in patients with diabetes as pri-
mary renal disease compared to patients with diabetes as a
co-morbid condition. Probably, PD patients with diabetes
as primary renal disease may have had higher levels of
(peritoneal) AGEs associated with endothelial dysfunction
and atherosclerotic cardiovascular disease [22,23].
There are potential limitations in the present study.
First, renal biopsies were not routinely obtained from our
patients with a clinical diagnosis of diabetic nephropathy
or diabetes as a co-morbid condition. Renal biopsies are
the reference standard to confirm whether diabetes is
indeed the primary cause of the nephropathy. However a
renal biopsy is an invasive procedure with a potential risk
of complications and is therefore often not performed in
a routine clinical setting. The diagnosis of diabetic
nephropathy was a diagnosis by exclusion and was based
on the opinion of the physician, reflecting common clini-
cal practice. We can not exclude that some patients
could have been misclassified, especially in patients with
diabetes as a co-morbid condition and a primary diagno-
sis of renal vascular disease. In that case it can not be
excluded that the diabetes has contributed largely to the
renal failure. However exclusion of patients with diabetes
as a co-morbid condition and a primary diagnosis of
renal vascular disease did not materially influence the
study results (data not shown). Second, the number of
patients with diabetes either as primary renal disease or
as a co-morbid condition was relatively small. Other lar-
ger and international studies had to be evaluated to con-
firm our study results. However, the percentage of
patients with diabetes in our cohort was comparable with
other studies [5]. Third, glycemic control of our patients
was not documented. However treatment of NECOSAD
patients was provided according to (inter)national guide-
lines, and it is unlikely that treatment for diabetes dif-
fered between the groups. Fourth, the number of patients
who received a renal transplant was higher in patients
without diabetes compared to patients with diabetes as
primary renal disease or patients with diabetes as a co-
morbid condition. Therefore a survival advantage might
exist for patients without diabetes mellitus. Finally, some
residual confounding by indication might still be present
when comparing HD to PD. On peritoneal dialysis survi-
val in patients with diabetes as a co-morbid condition
was substantially better compared to patients with dia-
betes as primary renal disease. Despite the difficulty in
categorization of patient groups these data were the best
available clinical data. Furthermore, random assignment
of treatment modality would hardly be feasible in patients
with ESRD. Future prospective analyses are required to
determine survival differences in other larger dialysis
cohorts between patients with diabetes mellitus as pri-
mary renal disease and patients with diabetes as a co-
morbid condition, and to establish if hemodialysis or
peritoneal dialysis is the optimal treatment regimen for
diabetic dialysis patients.
Further we adjusted our analyses for age and gender,
while we did not for cardiovascular disease. Cardiovascu-
lar disease is most likely on the causal path between dia-
betes and mortality and should therefore not be adjusted
for. Alternatively, it can be speculated that among
patients with diabetes as co-morbid condition (if diabetes
is not considered as the cause of renal disease), diabetes
may also not be the main cause of cardiovascular disease
as well. However, exploring this possibility and correcting
the main analyses also for cardiovascular disease, did not
change the results.
Conclusions
This study showed that survival in diabetic patients with
ESRD was worse compared to non-diabetic patients.
Mortality in patients with diabetes as primary renal dis-
ease was similar compared to patients with diabetes
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a very strong impact on survival even if it is not the pri-
mary cause of ESRD.
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